The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa)

Joseph Larmarange, Mamadou Hassimiou Diallo, Nuala McGrath, Collins Iwuji, Mélanie Plazy, Rodolphe Thiébaut, Frank Tanser, Till Bärnighausen, Deenan Pillay, François Dabis, Joanna Orne-Gliemann, ANRS 12249 TasP Study Group, Joseph Larmarange, Mamadou Hassimiou Diallo, Nuala McGrath, Collins Iwuji, Mélanie Plazy, Rodolphe Thiébaut, Frank Tanser, Till Bärnighausen, Deenan Pillay, François Dabis, Joanna Orne-Gliemann, ANRS 12249 TasP Study Group

Abstract

Introduction: The universal test and treat strategy (UTT) was developed to maximize the proportion of all HIV-positive individuals on antiretroviral treatment (ART) and virally suppressed, assuming that it will lead to a reduction in HIV incidence at the population level. The evolution over time of the cross-sectional HIV care cascade is determined by individual longitudinal trajectories through the HIV care continuum and underlying population dynamics. The purpose of this paper is to quantify the contribution of each component of population change (in- and out-migration, HIV seroconversion, ageing into the cohort and definitive exit such as death) on the HIV care cascade in the context of the ANRS 12249 Treatment as Prevention (TasP) cluster-randomized trial, investigating UTT in rural KwaZulu-Natal, South Africa, between 2012 and 2016.

Methods: HIV test results and information on clinic visits, ART prescriptions, viral load and CD4 count, migration and deaths were used to calculate residency status, HIV status and HIV care status for each individual on a daily basis. Position within the HIV care continuum was considered as a score ranging from 0 (undiagnosed) to 4 (virally suppressed). We compared the cascade score of each individual joining or leaving the population of resident adults living with HIV with the average score of their cluster at the time of entry or exit. Then, we computed the contribution of each entry or exit on the average cascade score and their annualized total contribution, by component of change.

Results: While the average cascade score increased over time in all clusters, that increase was constrained by population dynamics. Permanent exits and ageing into the people living with HIV cohort had a marginal effect. Both in-migrants and out-migrants were less likely to be retained at each step of the HIV care continuum. However, their overall impact on the cross-sectional cascade was limited as the effect of in- and out-migration balanced each other. The contribution of HIV seroconversions was negative in all clusters.

Conclusions: In a context of high HIV incidence, the continuous flow of newly infected individuals slows down the efforts to increase ART coverage and population viral suppression, ultimately attenuating any population-level impact on HIV incidence.

Clinical trial number: NCT01509508 (clinicalTrials.gov)/DOH-27-0512-3974 (South African National Clinical Trials Register).

Keywords: Cross-sectional cascade; HIV care continuum; Migration; Population dynamics; Public health; Rural South Africa; Structural drivers.

© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Dates of home‐based survey rounds activities by clusters, ANRS 12249 TasP trial (2012 to 2016). The light areas in round 1 indicate the time required to complete the initial census of the resident population.
Figure 2
Figure 2
Evolution over time of the population cross‐sectional HIV care cascade per group of clusters, ANRS 12249 TasP trial (2012 to 2016).
Figure 3
Figure 3
Trends of the average cascade score per cluster over time, ANRS 12249 TasP trial (2012 to 2016). Each line represents a different cluster. All clusters did not open at the same time (cf. Figure 1): 4 clusters opened in 2012, 6 in 2013 and 12 in 2014.
Figure 4
Figure 4
Annual growth rates of the resident PLWHIV population, by population change components and per cluster, ANRS 12249 TasP trial (2012 to 2016). Dotted lines indicate the sum of all rates, i.e. net annual population growth rate.
Figure 5
Figure 5
Position within the HIV care continuum at the date of entry/exit, by population change component, ANRS 12249 TasP trial (2012 to 2016).
Figure 6
Figure 6
Distribution of the differences between HIV care cascade score at entry/exit and the cluster average score at the same date, by population change component, ANRS 12249 TasP trial (2012 to 2016).
Figure 7
Figure 7
Annualized total contribution of population change on cluster average cascade score, by component of population change and per cluster, ANRS 12249 TasP trial (2012 to 2016). Dotted lines indicate the sum of the total contribution of in‐ and out‐migration. Black lines indicate the sum of total contribution of all events. Examples of reading: in cluster C01, in‐migration events reduced annually the cluster average cascade score by 0.127 while out‐migration events increased it by 0.161. Therefore, the overall contribution of migration is +0.034 per year.

References

    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV‐1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
    1. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.
    1. INSIGHT START Study Group , Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.
    1. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell M‐L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu‐Natal, South Africa. Science. 2013;339(6122):966–71.
    1. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test‐and‐treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
    1. Miller WC, Lesko CR, Powers KA. The HIV care cascade: simple concept, complex realization. Sex Transm Dis. 2014;41(1):41–2.
    1. UNAIDS . 90‐90‐90: An ambitious treatment target to help end the AIDS epidemic [Internet]. Geneva: UNAIDS; 2014. Oct [cited 11 October 2017]. Report No.: UNAIDS/JC2684. Available from:
    1. Haber N, Pillay D, Porter K, Bärnighausen T. Constructing the cascade of HIV care: methods for measurement. Curr Opin HIV AIDS. 2016;11(1):102–8.
    1. Dobra A, Bärnighausen T, Vandormael A, Tanser F. Space‐time migration patterns and risk of HIV acquisition in rural South Africa. AIDS. 2017;31(1):137–45.
    1. Tanser F, Bärnighausen T, Vandormael A, Dobra A. HIV treatment cascade in migrants and mobile populations. Curr Opin HIV AIDS. 2015;10(6):430–8.
    1. Haber N, Tanser F, Bor J, Naidu K, Mutevedzi T, Herbst K, et al. From HIV infection to therapeutic response: a population‐based longitudinal HIV cascade‐of‐care study in KwaZulu‐Natal, South Africa. Lancet HIV. 2017;4(5):e223–30.
    1. Zaidi J, Grapsa E, Tanser F, Newell M‐L, Bärnighausen T. Dramatic increase in HIV prevalence after scale‐up of antiretroviral treatment. AIDS. 2013;27(14):2301–5.
    1. Iwuji CC, Orne‐Gliemann J, Larmarange J, Okesola N, Tanser F, Thiebaut R, et al. Uptake of home‐based HIV testing, linkage to care, and community attitudes about ART in rural KwaZulu‐Natal, South Africa: descriptive results from the first phase of the ANRS 12249 TasP cluster‐randomised trial. PLoS Med. 2016;13(8):e1002107.
    1. Muhwava W, Hosegood V, Nyirenda M, Newell C, Herbst K, Newell M‐L. Levels and determinants of population migration in rural KwaZulu‐Natal, South Africa. Afr Popul Stud. 2010;24(3):259–80.
    1. Camlin CS, Hosegood V, Newell M‐L, McGrath N, Bärnighausen T, Snow RC. Gender, migration and HIV in rural KwaZulu‐Natal, South Africa. PLoS ONE. 2010;5(7):e11539.
    1. Hosegood V, McGrath N, Moultrie TA. Dispensing with marriage: marital and partnership trends in rural KwaZulu‐Natal, South Africa 2000‐2006. Demogr Res. 2009;20(20):279–312.
    1. Iwuji CC, Orne‐Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open‐label, community cluster randomised trial. Lancet HIV. 2018;5(3):e116–25.
    1. Iwuji CC, Orne‐Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations‐guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub‐district, KwaZulu‐Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013;14(1):230.
    1. Orne‐Gliemann J, Larmarange J, Boyer S, Iwuji C, McGrath N, Bärnighausen T, et al. Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health. 2015;15(1):209.
    1. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol. 2011;40(2):318–26.
    1. Chi BH, Yiannoutsos CT, Westfall AO, Newman JE, Zhou J, Cesar C, et al. Universal definition of loss to follow‐up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011;8(10):e1001111.
    1. Lessells RJ, Mutevedzi PC, Cooke GS, Newell M‐L. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu‐Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56(3):e79–86.
    1. R Development Core Team . R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available from:
    1. Jacob Bor, Till Bärnighausen, Colin Newell, Frank Tanser, Marie‐Louise Newell. Social exposure to an antiretroviral treatment programme in rural KwaZulu‐Natal. Trop Med Int Health. 2011;16(8):988–94.
    1. Plazy M, ElFarouki K, Iwuji C, Okesola N, Orne‐Gliemann J, Larmarange J, et al. Entry into care following universal home‐based HIV testing in rural KwaZulu‐Natal, South Africa: the ANRS TasP 12249 cluster‐randomized trial. J Int Aids Soc. 2015;18 (Suppl 4):78–79.
    1. Larmarange J, Diallo MH, Iwuji C, Orne‐Gliemann J, McGrath N, Plazy M, et al. Cascade of care of HIV seroconverters in the context of universal ‘Test and Treat’. In Seattle: abstract number 1018; 2017. [cited 1 March 2017]. Available from:

Source: PubMed

3
订阅